We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+39.07%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.38B
AUM Growth
+$198M
Cap. Flow
-$130M
Cap. Flow %
-5.45%
Top 10 Hldgs %
45.26%
Holding
80
New
15
Increased
16
Reduced
23
Closed
20

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$84.7M
2
INSM icon
Insmed
INSM
+$82.4M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$61.2M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$50.7M
5
AUTL
Autolus Therapeutics
AUTL
+$37.9M

Top Sells

Rank Stock Value
1
NVCR icon
NovoCure
NVCR
+$98.3M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$80M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$51.5M
4
KURA icon
Kura Oncology
KURA
+$43.5M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 96.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GHRS icon
51
GH Research
GHRS
$1.92B
$4.85M 0.2%
499,400
– –
JNCE
52
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$4.73M 0.2%
4,259,653
– –
IPSC icon
53
Century Therapeutics
IPSC
$364M
$3.57M 0.15%
695,845
-228,796
-25% -$2.16M
INZY
54
DELISTED
Inozyme Pharma
INZY
$3.41M 0.14%
3,250,000
– –
ASMB icon
55
Assembly Biosciences
ASMB
$498M
$2.38M 0.1%
152,786
-97,214
-39% -$1.66M
THRD
56
DELISTED
Third Harmonic Bio
THRD
$1.92M 0.08%
445,572
-822,648
-65% -$13.8M
AUPH icon
57
Aurinia Pharmaceuticals
AUPH
$1.95B
$1.4M 0.06%
324,238
-5,353,134
-94% -$31.1M
DNTH icon
58
Dianthus Therapeutics
DNTH
$5.69B
$1.19M 0.05%
187,500
-147,438
-44% -$2.61M
HOOK
59
DELISTED
HOOKIPA Pharma
HOOK
$1M 0.04%
124,037
-379,563
-75% -$4.11M
RETA
60
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$479K 0.02%
+12,600
New +$434K
ACET icon
61
Adicet Bio
ACET
$77.6M
– –
-51,594
Closed -$11.7M
AKRO
62
DELISTED
Akero Therapeutics
AKRO
– –
-790,926
Closed -$26.9M
ANAB icon
63
AnaptysBio
ANAB
$1.54B
– –
-360,000
Closed -$9.18M
ARDX icon
64
Ardelyx
ARDX
$1.24B
– –
-14,858,000
Closed -$17.7M
FATE icon
65
Fate Therapeutics
FATE
$275M
– –
-1,311,113
Closed -$29.4M
KALV
66
DELISTED
KalVista Pharmaceuticals
KALV
– –
-1,824,000
Closed -$26.5M
KROS icon
67
Keros Therapeutics
KROS
$197M
– –
-248,500
Closed -$9.35M
KURA icon
68
Kura Oncology
KURA
$793M
– –
-3,186,083
Closed -$43.5M
NVCR icon
69
NovoCure
NVCR
$1.76B
– –
-1,293,761
Closed -$98.3M
PASG icon
70
Passage Bio
PASG
$14.5M
– –
-71,953
Closed -$1.8M
RLMD icon
71
CALL
Relmada Therapeutics
RLMD
$540M
– –
-117,200
Closed -$4.34M
SDGR icon
72
Schrodinger
SDGR
$1.13B
– –
-170,000
Closed -$4.25M
VERV
73
DELISTED
Verve Therapeutics
VERV
– –
-775,000
Closed -$26.6M
GRTS
74
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-45,500
Closed -$117K
RETA
75
PUT
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-316,800
Closed -$7.96M
1 2
3
4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Deep Track Capital held 80 positions worth $2.38B, up 9.1% from $2.18B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Deep Track Capital withdrew a net $130M in Q4 2022, closing 20 positions and reducing 23 holdings. Its most notable exit was NovoCure, an estimated $98.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier.

Against the trend, Deep Track Capital opened a new position in Biogen worth $83.1M.

  • Deep Track Capital's largest Q4 2022 buy was Biogen: 300,000 shares worth $83.1M.
  • Deep Track Capital added most to DICE Therapeutics, Inc. Common Stock in Q4 2022, an estimated $23.9M increase.
  • Deep Track Capital's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $80M.
  • Deep Track Capital fully exited NovoCure in Q4 2022, selling an estimated $98.3M.
  • Deep Track Capital's ten largest holdings make up 45% of its $2.38B portfolio in Q4 2022.
  • Deep Track Capital opened 15 new positions and closed 20 in Q4 2022.
  • Deep Track Capital's portfolio value rose 9.1% quarter-over-quarter to $2.38B.

Based on Deep Track Capital's 13F filing for Q4 2022, filed 14 Feb 2023.